key: cord-0801044-0fq2ngcb authors: Teherán, Aníbal A.; Camero, Gabriel; Hernández, Carolina; Perez‐Garcia, Luis; Gúzman, Renato; Paniz‐Mondolfi, Alberto; Ramírez, Juan David title: Potential negative effects of the free use of chloroquine to manage COVID‐19 in Colombia date: 2020-06-05 journal: J Med Virol DOI: 10.1002/jmv.26059 sha: 23714cb087472a48253fb163222264ef0a060913 doc_id: 801044 cord_uid: 0fq2ngcb Coronavirus disease 2019 (COVID-19) pandemic has challenged healthcare systems around the world. Unfortunately, failure has ensued: high-income countries have succumbed to the global emergency despite highly prepared human and technological assets. There is no current consensus on pharmacological management of COVID-19, but chloroquine phosphate (CQ) has emerged as a possible therapeutical candidate. However, no conclusive evidence has been published on the efficacy of CQ against SARS-CoV-2 infection. The Colombian government has approved the use of CQ for COVID-19, a measure that could negatively impact a large number of patients who depend on this drug for the treatment of other life-threatening diseases such as malaria and rheumatic autoimmune diseases. Careful consideration should be taken by Colombian authorities regarding the use of CQ in context of the ongoing pandemic. This article is protected by copyright. All rights reserved. or as an extreme measure in patients with a high risk of death. However, its effectiveness against COVID-19 has recently been questioned, 9 and studies suggest that CQ should be used with caution in the treatment of severe presentations of disease based on its potential cardiotoxic side effects and increased lethality. 10 In response to this initiative, the World Health Organization issued a warning on how the use of unproven drugs could generate shortages to treat other diseases for which efficacy has already been proven, referring to chloroquine, commonly used to treat malaria and autoimmune disorders. 11 Recently, the Colombian government established that "after finding scientific evidence, the use of chloroquine and hydroxychloroquine is considered given the possibility that medical personnel may consider its use for the treatment of COVID-19". 12 However, this would be an off-label indication given that the effectiveness of chloroquine in treating patients with COVID-19 is supported mainly by in-vitro studies, animal models, anecdotic evidence and by ongoing clinical trials without definitive results. 6 Another problem is the limited sample size of many of these trials, and the possible selection bias towards critically ill patients with pneumonia. 6 recommending an off-label medication to healthcare personnel that lacks approval, regulation, and evidence of efficacy against COVID-19 pneumonia could generate misinformation among the general population, promoting massive panic-buying behaviors and creating an over-cost and shortage problem that may lead to a serious public health issue. On the other hand, a "kill two birds with one stone" approach would be favorable in particular epidemiological settings such as COVID-19 and malaria overlapping areas. This is the case of the Colombian Amazon department-the 7th most affected by COVID-19 and one of the five Colombian departments without ICU services 18 -where long-time prevalent malaria 15 and the abrupt increase in COVID-19 cases 19 have started to overlap. Capitalizing on the use of CQ to treat both conditions could result in advantageous and is definitely a topic that deserves further investigation. As of 25th April 2020, there are 23 clinical trials registered for the management of COVID-19 using chloroquine in "recruiting" (n: 11), "not yet recruiting" (n: 10) and "enrolling by invitation" (n: 2) phases, and to date, the two most rigorous clinical trials published with partial or complete results have not shown favorability, with one of them having to be suspended 6 days after beginning due to elevated rates of adverse cardiac effects. 13, 20 In addition to the nonsupporting Impact of nonpharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand Estimating risk for death from 2019 novel coronavirus disease, China Monitoring transmissibility and mortality of COVID-19 in Europe Role of chloroquine and hydroxychloroquine in the treatment of COVID-19 infection-a systematic literature review [published online ahead of print Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries Genetic profiles in pharmacogenes indicate personalized drug therapy for COVID-19 Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID-19 en establecimientos de atención de la salud -Recomendaciones basadas en consenso de expertos e informadas en la evidencia Chloroquine and hydroxychloroquine in covid-19 Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who-director-general-s-opening-remarks-at-the-media-briefing-on-covid Hidroxicloroquina y cloroquina se podrán usar para tratamiento de covid -19 Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination Informe de evento Malaria Colombia, primer semestre 2019 Malaria intensity in Colombia by regions and populations Will Colombian intensive care units collapse due to the COVID-19 pandemic? Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19 The authors declare that there are no conflict of interests. http://orcid.org/0000-0002-1344-9312